Search research articles
Contact Us
Filters
Showing results (81-90 of 99) with videos related to
Page
of 10
Sort By:
Plos One
|
February 19, 2015
Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression
Nitin Patel, Tatsuo Itakura, Shinwu Jeong, et al.
Journal of Genetics
|
February 24, 2021
Elucidation of genotype-environment interactions and genetic stability parameters for yield, quality and agromorphological traits in ashwagandha (<i>Withania somnifera</i> (L.) Dunal)
Mithlesh Kumar, Manubhai Patel, Ravindrasingh Chauhan, et al.
Mabs
|
March 2, 2023
High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions
André Luiz Lourenço, Shih-Wei Chuo, Markus F Bohn, et al.
Current Medical Research and Opinion
|
August 12, 2024
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison
Noffar Bar, Joris Diels, Suzy van Sanden, et al.
Advances in Therapy
|
July 4, 2025
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting
Rafael Fonseca, Joris Diels, Francesca Ghilotti, et al.
Nature Reviews. Drug Discovery
|
October 10, 2009
The future of drug development: advancing clinical trial design
John Orloff, Frank Douglas, Jose Pinheiro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2024
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials
Kwee Yong, Hermann Einsele, Jordan M Schecter, et al.
Cancer Medicine
|
July 28, 2025
Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum Database
Binod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
Cancer Letters
|
February 22, 2023
Lymphocyte antigen 6K signaling to aurora kinase promotes advancement of the cell cycle and the growth of cancer cells, which is inhibited by LY6K-NSC243928 interaction
Benson Chellakkan Selvanesan, Sheelu Varghese, Justyna Andrys-Olek, et al.
Journal of Patient-Reported Outcomes
|
March 13, 2026
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial
Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 99) with videos related to
Sort By:
Page
of 10
Plos One
|
February 19, 2015
Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression
Nitin Patel, Tatsuo Itakura, Shinwu Jeong, et al.
Journal of Genetics
|
February 24, 2021
Elucidation of genotype-environment interactions and genetic stability parameters for yield, quality and agromorphological traits in ashwagandha (<i>Withania somnifera</i> (L.) Dunal)
Mithlesh Kumar, Manubhai Patel, Ravindrasingh Chauhan, et al.
Mabs
|
March 2, 2023
High-throughput optofluidic screening of single B cells identifies novel cross-reactive antibodies as inhibitors of uPAR with antibody-dependent effector functions
André Luiz Lourenço, Shih-Wei Chuo, Markus F Bohn, et al.
Current Medical Research and Opinion
|
August 12, 2024
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2-4 prior lines of therapy: a matching-adjusted indirect comparison
Noffar Bar, Joris Diels, Suzy van Sanden, et al.
Advances in Therapy
|
July 4, 2025
Survival Outcomes with Cilta-cel Versus Conventional Treatment Regimens for Patients with Lenalidomide-Refractory Multiple Myeloma Using Inverse Probability of Treatment Weighting
Rafael Fonseca, Joris Diels, Francesca Ghilotti, et al.
Nature Reviews. Drug Discovery
|
October 10, 2009
The future of drug development: advancing clinical trial design
John Orloff, Frank Douglas, Jose Pinheiro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2024
Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials
Kwee Yong, Hermann Einsele, Jordan M Schecter, et al.
Cancer Medicine
|
July 28, 2025
Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum Database
Binod Dhakal, Hermann Einsele, Jordan M Schecter, et al.
Cancer Letters
|
February 22, 2023
Lymphocyte antigen 6K signaling to aurora kinase promotes advancement of the cell cycle and the growth of cancer cells, which is inhibited by LY6K-NSC243928 interaction
Benson Chellakkan Selvanesan, Sheelu Varghese, Justyna Andrys-Olek, et al.
Journal of Patient-Reported Outcomes
|
March 13, 2026
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial
Roberto Mina, Anne K Mylin, Hisayuki Yokoyama, et al.
Page
of 10